1/24/2013

The FDA authorized the use of Roche Holding's Avastin, or bevacizumab, with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin chemotherapy, for patients with metastatic colorectal cancer whose condition worsened after previous treatment with the drug. Avastin was developed by Roche unit Genentech.

Related Summaries